These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2948537)

  • 1. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
    Plowman PN; Nicholson RI; Walker KJ
    Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer.
    Walker KJ; Turkes A; Williams MR; Blamey RW; Nicholson RI
    J Endocrinol; 1986 Nov; 111(2):349-53. PubMed ID: 2947964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
    Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
    Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer.
    Nicholson RI; Walker KJ; Turkes A; Dyas J; Plowman PN; Williams M; Blamey RW
    J Steroid Biochem; 1985 Nov; 23(5B):843-7. PubMed ID: 2934580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
    Robertson JF; Walker KJ; Nicholson RI; Blamey RW
    Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin.
    Dowsett M; Cantwell B; Lal A; Jeffcoate SL; Harris AL
    J Clin Endocrinol Metab; 1988 Apr; 66(4):672-7. PubMed ID: 2964454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.
    Klijn JG; de Jong FH
    Lancet; 1982 May; 1(8283):1213-6. PubMed ID: 6122975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
    Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
    Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
    Mahler C; Verhelst J; Chaban M; Denis L
    Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Buserelin therapy in postmenopausal patients with advanced breast carcinoma].
    Vici P; Veltri E; Carpano S; Di Lauro L; Lopez M
    Clin Ter; 1991 Feb; 136(3):195-9. PubMed ID: 1827382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoladex: therapeutic effects in postmenopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
    Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
    Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer--a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group.
    Kaufmann M; Jonat W; Schachner-Wünschmann E; Bastert G; Maass H
    Onkologie; 1991 Feb; 14(1):22-4, 26-8, 30. PubMed ID: 1829149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
    Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
    Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
    Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118-630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer.
    Kuber W; Viehberger G; Zeillinger R; Spona J
    Urol Res; 1991; 19(1):19-24. PubMed ID: 1827557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
    Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
    Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.